The immunomodulatory potential of thymulin in the perinatal epithelium is not well characterized. In an in vitro model of fetal alveolar type II epithelial cells, we investigated the exhibition of an anti-inflammatory activity of this peptide hormone. Thymulin selectively ameliorated, in a dose-dependent manner, the endotoxin-induced release of IL-1␤ (IC 50 ‫؍‬ 657 ng ⅐ ml ؊1 ), but showed no inhibitory effect on IL-6 and TNF-␣. Zinc, an anti-inflammatory antioxidant, which is required for the biological activity of thymulin, reduced the secretion of IL-1␤ (IC 50 ‫؍‬ 62 M), TNF-␣ (IC 50 ‫؍‬ 1000 M), and, to a lesser extent, IL-6. This cation (100 M) amplified the effect of thymulin on IL-1␤ and TNF-␣ (IC 50 < 0.1 ng ⅐ ml ؊1 ), but not on IL-6. Analysis of whether thymulin is up-regulating a counterpart antiinflammatory signaling loop revealed the involvement of an IL-10-sensitive pathway. These results indicate that thymulin acts as a novel dual immunoregulator by enhancing an anti-inflammatory cytoprotective response and depressing an inflammatory signal, an effect synergistically amplified, in part, by cationic zinc.
Thymulin is a nonapeptide hormone with immunoregulatory actions, thereby providing an interface between neuroendocrine-immune communication systems (1, 2) . Originally known as "serum thymic factor" (FTS) (3) , thymulin binds to a carrier protein and zinc to exert its modulatory properties (4) . The biological activity of thymulin is dependent on equimolar interaction with zinc, whose bioavailability affects cellular immune effectiveness under physiological and pathophysiological conditions (5, 6) . It has been shown that thymulin is capable of modulating pro-inflammatory cytokines in disease (7) , providing an evidence for a novel anti-inflammatory potential and participation in signaling pathways governing genetically controlled cell fate and apoptosis (1) (2) (3) 8) .
The underlying mechanisms of thymulin mediated immunoregulation are not fully understood. It has been reported that the effects of thymulin in downregulating an inflammatory signal are mediated, at least in part, by modulating intracellular cyclic nucleotides (9, 10) . In addition to the potent antiinflammatory properties of thymulin, zinc can synergistically down-regulate a pro-inflammatory signal by reducing the release of inflammatory mediators (11, 12) and by acting as a cytoprotective antioxidant in the face of an oxidative challenge (13, 14) . Of particular importance, zinc was shown to be required in mediating antioxidant-dependent inhibition of the redoxsensitive nuclear factor-B (NF-B), a transcription factor essential to the expression of pro-inflammatory genes encoding cytokines (15, 16) , and particularly involved in regulating apoptosis (2, 8, 17) . In addition, a redox-sensitive mechanism involving Zn 2ϩ has been implicated in regulating the DNA binding kinetics of NF-B in vitro (18) . The anti-inflammatory property assigned to thymulin-Zn 2ϩ in the perinatal lung, however, has yet to be ascertained.
These observations, therefore, prompted us to investigate whether thymulin-Zn 2ϩ has an immunomodulatory potential in the alveolar epithelium. We particularly show that thymulin differentially down-regulates the endotoxin-induced secretion of pro-inflammatory cytokines (IL-1␤, IL-6, and TNF-␣), and that this effect is accompanied by enhancing an antagonistic, cytoprotective anti-inflammatory response through an IL-10-sensitive pathway. The immunomodulatory property of thymulin is partially amplified in a synergistic manner by cationic zinc which, on its own, non-selectively suppressed the release of pro-inflammatory mediators. We conclude that thymulin regulates an inflammatory signal within the alveolar space by acting as a dual immunoregulator and subsequently up-regulating a counterinflammatory mechanism. This bears particular relevance to the pediatric treatment of respiratory distresses where cytokines are recognized as major participants in their pathophysiology, and determine the specificity by which the therapeutic potential of thymulin-Zn 2ϩ would be explored to regulate and manipulate genetically controlled cell fate in premature infants receiving clinical oxygen therapy.
MATERIALS AND METHODS
Chemicals and reagents. Unless otherwise indicated, chemicals of the highest analytical grade were purchased from Sigma-Aldrich. All experimental procedures involving the use of live animals were reviewed and approved under the Animals (Scientific Procedures) Act, 1986 (UK).
Primary cultures of alveolar epithelia. Fetal alveolar type II (fATII) epithelial cells were isolated from lungs of fetuses at day 19 of gestation, essentially as reported elsewhere (17, 19) . Epithelia were harvested and grown (5 ϫ 10 6 ) at 152 Torr (Ϸ21% O 2 ) and 37°C for 24 h in serum-free PC-1 media. We have found that the adenylate energy charge, an index of cell viability and competence, remained Ն0.7 and transepithelial monolayer resistance was monitored constant at Ն250 -300 ⍀cm 2 (17, 19, 24) .
Thymic hormone immunomodulatory effect on LPS-induced cytokine release. The carboxymethyl cellulose (1% CMC in 150 mM NaCl) was used as a carrier in which thymic hormones were administered (20) . Cells were stimulated with LPS (1 g ⅐ ml Ϫ1 ) and simultaneously cultured for 4 h in the presence of thymulin (0 -1000 ng ⅐ ml Ϫ1 ). Cell-free supernatants were subsequently assayed for IL-1␤, IL-6, TNF-␣ (R&D Systems) and IL-10 (Biosource International) by sandwich enzyme-linked immunosorbent assay (ELISA).
Zinc immunomodulatory effect on LPS-induced cytokine release.
Since the biological activity of thymic hormones is dependent on equimolar interaction with zinc (21), we reasoned that thymulin might synergistically interact with zinc to modulate the secretory profile of cytokines in vitro. Subsequently, cells were exposed to LPS (1 g ⅐ ml Ϫ1 ) in the presence of zinc (ZnCl 2 ; 100 M) and thymulin. The dose-response curve for ZnCl 2 (0 -1000 M) was separately performed. The thymulin-Zn 2ϩ medium was thoroughly shaken and maintained at room temperature for 10 min to permit thymulin-Zn 2ϩ binding (4); this stock solution was briefly oxygenated (95% O 2 /5% CO 2 ) and warmed to 37°C immediately before dilution and addition to monolayers.
Statistical analysis and data presentation. Data are presented as means Ϯ SEM of at least 3 independent cell cultures. Statistical evaluation of the difference in mean separation was performed by one-way analysis of variance (ANOVA), followed by post hoc Tukey's test, and the a priori level of significance at 95% confidence level was considered at P Ͻ 0.05.
RESULTS AND DISCUSSION
The present study shows for the first time that thymulin-Zn 2ϩ exerts a selective inhibitory influence on the in vitro secretion of cytokines by the fetal alveolar epithelium. We particularly show that the immunomodulatory potential mediated by thymulin is exhibited by down-regulating an inflammatory signal through differential reduction of LPS-induced release of IL-1␤, IL-6, and TNF-␣. This selective inhibition is accompanied by an up-regulation of an anti-inflammatory response mediated by IL-10. In addition, we show that cationic zinc, on its own, is capable of exhibiting an anti-inflammatory response as evident from the reduction of pro-inflammatory cytokine release. Of particular interest, the observation that the anti-inflammatory potential of thymulin is further amplified in the presence of Zn 2ϩ , suggesting synergism in depressing LPS-induced cytokine secretion, a condition relevant to pathophysiology in the developing lung. This leads us to suggest that thymulin exhibits an anti-inflammatory activity in the alveolar epithelium by acting as a novel dual regulator: It down-regulates a pro-inflammatory signal and at the same time amplifies an antiinflammatory response. Although this effect is synergistically enhanced, at least in part, with Zn 2ϩ , the mechanism by which Zn 2ϩ exerts its immunomodulatory potential is independent of up-regulating IL-10.
Analysis of Thymulin-Dependent Inhibition of LPS-Induced Cytokine Release
The anti-inflammatory potential of thymulin is evident with dose-dependent inhibition of LPS-induced cytokine secretion, as shown in Fig. 1 . The carrier protein used to administer thymulin has no effect on the cytokine profile, in contrast to LPS (1 g ⅐ ml Ϫ1 ) which caused Ϸ10-fold elevation in IL-1␤ (Fig. 1A) . Although LPS induced the release of IL-6 (Ϸ14-fold), the effect of thymulin on this cytokine is not prominent, as its concentration remained elevated even in the presence of the highest dosage used for thymulin (1 g ⅐ ml Ϫ1 ) (Fig. 1B) . Similar observations are reported for TNF-␣ (Ϸ5-fold) whose concentration remained elevated across the dose range of thymulin (Fig. 1C) . This suggests that thymulin differentially and selectively regulates the endotoxin-induced release of proinflammatory cytokines, with prominent inhibitory effect on IL-1␤.
Analysis of Zn 2ϩ -Dependent Inhibition of LPS-Induced Cytokine Release
It is evident that cationic zinc possesses an antiinflammatory property in the alveolar epithelium. In a manner similar to thymulin, and even more potently, Zn 2ϩ reduced in a dose-dependent manner the LPS-induced cytokine secretion (Fig. 2) . Zinc on its own, like CMC (1%) has no effect on the cytokine profile. Substantial reduction in IL-1␤ was observed with ascending Zn 2ϩ concentration ( Fig. 2A) , suggesting an immunomodulatory potential of this cation. Although the effect of Zn 2ϩ on LPS-induced IL-6 release is less prominent than IL-1␤, this cation was able to reduce IL-6 at the highest concentration used (1 mM) (Fig. 2B) . In a manner similar to its effect on IL-1␤, Zn 2ϩ potently reduced the induced production of TNF-␣ spanning the dose-response curve (Fig. 2C) . Although the effect of thymulin is selective, in that it was able to reduce the release of IL-1␤ but not other cytokines, the effect of Zn 2ϩ is nonselective, as it was able to reduce though differentially the release of all cytokines investigated. The anti-inflammatory-like property of Zn 2ϩ in vitro, therefore, forms a very likely target for screening a therapeutic potential of this cation, in conjunction with thymulin, in the treatment of disease conditions in the lung in which cytokines are major participants in their pathophysiology, as has been shown, for example, in cystic fibrosis (22) .
FIG. 2. Cytokine profile in the presence of Zn 2ϩ . (A) The doseresponse curve showing the effect of Zn 2ϩ on LPS-induced IL-1␤ release (4 h). (B) The effect of Zn
2ϩ on IL-6 are less prominent than on IL-1␤, although this cation was able to depress LPS-induced IL-6 secretion at the highest dose used (1 mM). (C) The effect of Zn 2ϩ on TNF-␣ release showing significant reductions similar to IL-1␤. P Ͻ 0.05, compared to control; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, compared to LPS. n ϭ 4, which represents the number of independent experiments in duplicate.
FIG. 1. Cytokine profile in the presence of thymulin. (A) The dose-response curve showing the effect of thymulin on LPS-induced IL-1␤ release (4 h). (B)
The effect of thymulin on IL-6 is less prominent than on IL-1␤. (C) No major changes, like IL-6, are reported with thymulin effect on LPS-induced TNF-␣ release. P Ͻ 0.05, compared to control; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001, compared to LPS. n ϭ 4, which represents the number of independent experiments in duplicate.
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Analysis of Thymulin/Zn 2ϩ -Dependent Synergism in Inhibiting LPS-Induced Cytokine Release
The biological activity of thymulin is regulated by an interaction with Zn 2ϩ in equilibrium (21) . The degree of inhibition of LPS-induced cytokine production is synergistically enhanced with a combination of thymulin and Zn 2ϩ . As shown in Fig. 3 (Fig. 3B) , contrary to the effect on TNF-␣ (Fig. 3C) reduced cytokine release more prominently in the presence of lower doses of thymulin (1 and 10 ng ⅐ ml Ϫ1 ) than in the presence of higher doses. The minimum contributing effective inhibitory concentration (IC 50 ) of thymulin in the presence or absence of Zn 2ϩ is given in Table 1 . IC 50 was determined from the linear regression of negative slope obtained with ascending concentration of thymulin and Zn 2ϩ . This analysis revealed a prominent effect of thymulin on IL-1␤, the effect of Zn 2ϩ on IL-1␤, IL-6 and TNF-␣, and the synergistic effect on IL-1␤ and TNF-␣, but not on IL-6.
Analysis of the Effect of Thymulin/Zn 2ϩ on UpRegulating an Anti-inflammatory Loop via IL-10
Whether the immunoregulatory potential assigned to thymulin is dependent on an IL-10 mediated pathway in not known in the alveolar epithelium. Spanning the profile of this cytokine across the concentration range of thymulin, we found that thymulin amplified the release of IL-10 by LPS (Fig. 4) . Noticeably, the lower range of the dose-response curve of thymulin enhanced LPS-induced IL-10 secretion, a reversible effect shown to return to LPS baseline at the upper range of the dose-response curve. Although the molecular basis of this mechanism has yet to be identified, it is clear that thymulin is acting as a novel dual regulator of cytokine release induced by endotoxin.
Paradoxically, Zn 2ϩ in a manner antagonizing the effect of thymulin reduced LPS-induced IL-10 release, similar to its effect on other cytokines. This is in accord with the observation that Zn 2ϩ is capable of normalizing the peripheral release of cytokines, including IL-6
TABLE 1
Analysis of the 50% Minimum Effective Inhibitory Concentration (IC 50 ) of Thymulin and Zinc on LPS-Induced Cytokine Release in the Alveolar Epithelium
Note. Data are presented as mean Ϯ SEM. n ϭ 4. ND, nondetectable (IC 50 Ͼ dose range). and IL-10, in chronic disease (23) . The ability of Zn 2ϩ to synergistically amplify the effect of thymulin on proinflammatory cytokines, and its failure to synergise an anti-inflammatory loop, suggests that pathways that are independent of IL-10 mediate its immunomodulatory effects. In contrast, the effect of thymulin in downregulating a pro-inflammatory signal is mediated, at least in part, by an IL-10-sensitive mechanism.
Gene promoters for cytokines contain multiple cisacting motifs including those that bind such transcription factors as NF-B. It has been shown previously that IL-10 selectively inhibited NF-B activation, a phenomenon well correlated with dose-dependent inhibition of the release of pro-inflammatory cytokines (25) . IL-10 action on NF-B involves the blockade of a reaction required for release of IB from the complex in intact cells. Experiments using cell-free preparations have suggested that protein kinase C phosphorylates IB causing its release and ensuing activation of NF-B complex (26) . There is conclusive supporting evidence from our laboratory suggesting the involvement of a NF-B-sensitive pathway mediating the inhibitory effect of thymulin-Zn 2ϩ on the release of pro-inflammatory mediators (24; Haddad et al., unpublished observations). Thymulin and zinc, separately and synergistically, substantially abrogated and in a dose-dependent manner the nuclear translocation and activation of NF-B, suggesting particular involvement of a signaling transduction mechanism mediating its effect on the expression of pro-inflammatory genes. This observation is in accord with the report implicating zinc in antioxidant-mediated mechanism transduced through NF-B (27) . In addition, thymulin and zinc were able to reduce the ubiquitination and proteasome degradation of IB-␣, the major inhibitor of the Rel family, supporting the notion that both factors are involved in retarding nuclear translocation and activation of NF-B, a pathway that subsequently leads to down-regulation of the downstream cytokine expression and release (Haddad et al., unpublished observations) . Accordingly, it is very likely that thymulin ability to down-regulate the release of cytokines, which is IL-10 sensitive, is dependent on the inhibition of a kinase that subsequently phosphorylates IB-␣, thereby preventing the unmasking of NF-B localization sequence and subsequent nuclear translocation. This ultimately leads to suppression of switching-on the promoters of genes encoding pro-inflammatory cytokines. We are currently extending these observations to investigate a particular role of thymulin-Zn 2ϩ in modulating intracellular redox potential via the glutathionedependent regulation of selective protein kinases, such as protein kinase C and mitogen-activated protein kinase (MAPK p38), and NF-B activation, and whether this pathway is likely to allow the differential expression of apoptosis signaling cofactors in the alveolar epithelium and in the developing lung (17) .
CONCLUSIONS
In summary, this report presents a novel immunomodulatory potential of thymulin and zinc in the alveolar epithelium. Our results are highlighted as follows: (i) thymulin exhibits a differential and selective inhi- P Ͻ 0.05, compared to control; *P Ͻ 0.05, **P Ͻ 0.01, compared to LPS. The sign (3) denotes an inductive, whereas (4) a suppressive exhibition of the induced production of IL-10. n ϭ 4, which represents the number of independent experiments in duplicate.
bition of the release of pro-inflammatory cytokines; (ii) this effect is mediated, at least in part, by amplifying an anti-inflammatory signaling loop through an IL-10 sensitive pathway; (iii) zinc possesses a non-selective anti-inflammatory potential, an effect which is not dependent on up-regulating IL-10; and (iv) the immunoregulatory property assigned to thymulin is partially enhanced in the presence of Zn 2ϩ . This exhibition of an immunomodulatory potential of thymulin-Zn 2ϩ bears clinical consequences for the pediatric treatment of respiratory distresses commonly witnessed in the developing lung (17, 19, 24) , whereby cytokines are regarded as major participants in their pathophysiology.
